Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

281. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes Full Text available with Trip Pro

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or placebo in a randomized, double-blind trial assessing safety, insulin dose, glycemic control, and other metabolic parameters over 29 days (...) of treatment.In the sotagliflozin-treated group, the percent reduction from baseline in the primary end point of bolus insulin dose was 32.1% (P = 0.007), accompanied by lower mean daily glucose measured by continuous glucose monitoring (CGM) of 148.8 mg/dL (8.3 mmol/L) (P = 0.010) and a reduction of 0.55% (5.9 mmol/mol) (P = 0.002) in HbA1c compared with the placebo group that showed 6.4% reduction in bolus insulin dose, a mean daily glucose of 170.3 mg/dL (9.5 mmol/L), and a decrease of 0.06% (0.65 mmol/mol

2015 EvidenceUpdates Controlled trial quality: predicted high

282. Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis Full Text available with Trip Pro

Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis Nocturnal hypoglycemia can cause seizures and is a major impediment to tight glycemic control, especially in young children with type 1 diabetes. We conducted an in-home randomized trial to assess the efficacy and safety of a continuous glucose monitor-based overnight predictive low-glucose suspend (PLGS) system.In two age-groups of children with type 1 diabetes (11-14

2015 EvidenceUpdates Controlled trial quality: uncertain

283. Low-dose vs standard-dose insulin in pediatric diabetic ketoacidosis: a randomized clinical trial

Low-dose vs standard-dose insulin in pediatric diabetic ketoacidosis: a randomized clinical trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2015 PedsCCM Evidence-Based Journal Club

284. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. Full Text available with Trip Pro

Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. To investigate the long term effects of continuous subcutaneous insulin infusion (insulin pump therapy) on cardiovascular diseases and mortality in people with type 1 diabetes.Observational study.Swedish National Diabetes Register, Sweden 2005-12.18,168 people with type 1 diabetes, 2441 using insulin pump therapy and 15,727 using multiple daily insulin (...) injections.Cox regression analysis was used to estimate hazard ratios for the outcomes, with stratification of propensity scores including clinical characteristics, risk factors for cardiovascular disease, treatments, and previous diseases.Follow-up was for a mean of 6.8 years until December 2012, with 114,135 person years. With multiple daily injections as reference, the adjusted hazard ratios for insulin pump treatment were significantly lower: 0.55 (95% confidence interval 0.36 to 0.83) for fatal coronary

2015 BMJ

285. Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance. (Abstract)

Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance. Diabetes is associated with long-term damage, dysfunction and failure of various organs, especially the eyes, kidneys, nerves, heart and blood vessels. The risk of developing type 2 diabetes increases with age, obesity and lack of physical activity. Insulin resistance is a fundamental aspect of the aetiology of type 2 diabetes. Insulin resistance has been shown to be associated (...) with atherosclerosis, dyslipidaemia, glucose intolerance, hyperuricaemia, hypertension and polycystic ovary syndrome. The mineral zinc plays a key role in the synthesis and action of insulin, both physiologically and in diabetes mellitus. Zinc seems to stimulate insulin action and insulin receptor tyrosine kinase activity.To assess the effects of zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.This review is an update of a previous Cochrane systematic review

2015 Cochrane

286. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. (Abstract)

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. For patients with type 2 diabetes who do not achieve target glycaemic control with conventional insulin treatment, advancing to a basal-bolus insulin regimen is often recommended. We aimed to compare the efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist (...) dulaglutide with that of insulin glargine, both combined with prandial insulin lispro, in patients with type 2 diabetes.We did this 52 week, randomised, open-label, phase 3, non-inferiority trial at 105 study sites in 15 countries. Patients (aged ≥18 years) with type 2 diabetes inadequately controlled with conventional insulin treatment were randomly assigned (1:1:1), via a computer-generated randomisation sequence with an interactive voice-response system, to receive once-weekly dulaglutide 1·5 mg

2015 Lancet Controlled trial quality: predicted high

287. Insulin degludec (Tresiba) - Treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year

Insulin degludec (Tresiba) - Treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year Published 11 May 2015 Statement of Advice: insulin degludec (Tresiba ® ) SMC No. (1060/15) Novo Nordisk Limited 10 April 2015 ADVICE: in the absence of a submission from the holder of the marketing authorisation Insulin degludec (Tresiba) is not recommended for use within NHS Scotland. Indication under review: Treatment of diabetes mellitus in adolescents and children from (...) the age of 1 year. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. SMC previously assessed insulin degludec (Tresiba) for the treatment of diabetes mellitus in adults (856/13) and advised that it is not recommended for use within NHS Scotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents

2015 Scottish Medicines Consortium

288. High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error

High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error - GOV.UK GOV.UK uses cookies to make the site simpler. or Search High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error Several new high strength insulin products are now on the market. The European Medicines Agency is consulting (...) on guidance to minimise the risk of medication error. Published 29 April 2015 From: Therapeutic area: Contents Public consultation It is likely that further such insulin products will come to market over the next few years. This draft guidance summarises ways to minimise the risk of medication errors with high strength, fixed combination and biosimilar insulin products already on the market. We encourage you to comment on the risk minimisation strategy for high strength and fixed combination insulin

2015 MHRA Drug Safety Update

289. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. Full Text available with Trip Pro

Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. Exposing the oral mucosa to antigen may stimulate immune tolerance. It is unknown whether treatment with oral insulin can induce a tolerogenic immune response in children genetically susceptible to type 1 diabetes.To assess the immune responses and adverse events associated with orally administered insulin in autoantibody-negative, genetically at-risk (...) children.The Pre-POINT study, a double-blind, placebo-controlled, dose-escalation, phase 1/2 clinical pilot study performed between 2009 and 2013 in Germany, Austria, the United States, and the United Kingdom and enrolling 25 islet autoantibody-negative children aged 2 to 7 years with a family history of type 1 diabetes and susceptible human leukocyte antigen class II genotypes. Follow-up was completed in August 2013.Children were randomized to receive oral insulin (n = 15) or placebo (n = 10) once daily

2015 JAMA Controlled trial quality: predicted high

290. Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes

Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along (...) . It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

291. Insulin Pens in Acute Care Settings

Insulin Pens in Acute Care Settings Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Insulin Pens in Acute Care Settings: Safety, Cost-Effectiveness, and Guidelines DATE

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

292. Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. Full Text available with Trip Pro

Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. Insulin resistance and hyperandrogenism are the cardinal features of polycystic ovary syndrome (PCOS). Women with insulin receptor (INSR) mutations develop severe hyperandrogenism secondary to hyperinsulinaemia. We hypothesised that insulin might drive adipose testosterone generation from androstenedione through aldoketoredutase type 3 (AKR1C3 (...) ) in women with insulin resistance. Here we assessed the effect of insulin on AKR1C3 activity in vivo and in vitro.Ten women with PCOS, ten healthy controls, and three women with INSR mutations underwent dehydroepiandrosterone (DHEA) challenge; serum androgens were measured every 30 min for 4 h after ingestion of 100 mg DHEA. Additionally, paired subcutaneous and omental fat samples were obtained during abdominal surgery from 38 women. AKR1C3 expression was measured by real-time PCR. Serum steroids

2015 Lancet

293. [Insulin degludec: benefit assessment according to section 35a Social Code Book V (dossier assessment)]

[Insulin degludec: benefit assessment according to section 35a Social Code Book V (dossier assessment)] Insulin degludec – nutzenbewertung gemass 35a SGB V [Insulin degludec: benefit assessment according to section 35a Social Code Book V (dossier assessment)] Insulin degludec – nutzenbewertung gemass 35a SGB V [Insulin degludec: benefit assessment according to section 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec – nutzenbewertung gemass 35a SGB V. [Insulin degludec: benefit assessment according to section 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 230. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cost-Benefit Analysis

2015 Health Technology Assessment (HTA) Database.

294. Insulin degludec/Insulin aspart (Ryzodeg 70/30)

Insulin degludec/Insulin aspart (Ryzodeg 70/30) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203313Orig1s000 203314Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 203313 and 203314 Priority or Standard Class 2 resubmission Submit Date(s) 26 March 2015 Received Date(s) 26 March 2015 PDUFA Goal Date 26 September 2015 Division / Office DMEP/ODEII Reviewer Name(s) Tania A. Condarco Review Completion Date 31 August 2015 Established Name Insulin (...) degludec Insulin degludec/Insulin aspart 70/30 (Proposed) Trade Name Tresiba for insulin degludec; Ryzodeg 70/30 for insulin degludec/insulin aspart 70/30 Therapeutic Class Tresiba: Long-acting (basal) insulin analog; Ryzodeg: Fixed-ratio combination of long- and short-acting insulin analogs Applicant Novo Nordisk Formulation(s) Tresiba: IDeg U100 (600 nmol/mL) and IDeg U200 (1200 nmol/mL) Ryzodeg Dosing Regimen Individualized dose administered subcutaneously once daily using a fixed or flexible dosing

2015 FDA - Drug Approval Package

295. Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin

Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Article Text Therapeutics/Prevention Systematic review with meta analysis In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Dana Carroll , Kristi W Kelley

2015 Evidence-Based Medicine

296. Tresiba (insulin degludec injection) - To improve blood sugar (glucose) control in adults with diabetes mellitus

Tresiba (insulin degludec injection) - To improve blood sugar (glucose) control in adults with diabetes mellitus Tresiba (degludec) and Ryzodeg U.S. Department of Health and Human Services Search FDA Submit search Tresiba (degludec) and Ryzodeg Company: Novo Nordisk, Inc. Application No.: 203313Orig1 and 203314Orig1 Approval Date: September 25, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

297. Insulin degludec (addendum to commission A15-10)

Insulin degludec (addendum to commission A15-10) 1 Translation of addendum A15-26 Insulin degludec (Addendum zum Auftrag A15-10) (Version 1.1; Status: 7 August 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 7 August 2015 1.1 Commission: A15-26 Version: Status: IQWiG Reports – Commission No. A15-26 Insulin degludec (Addendum to Commission A15-10 (...) ) 1 Addendum A15-26 Version 1.1 Insulin degludec (Addendum to Commission A15-10) 7 August 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec (Addendum to Commission A15-10) Commissioning agency: Federal Joint Committee Commission awarded on: 13 July 2015 Internal Commission No.: A15-26 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

298. Insulin degludec/liraglutide (Addendum to Commission A15-15)

Insulin degludec/liraglutide (Addendum to Commission A15-15) 1 Translation of addendum A15-36 Insulin degludec/Liraglutid (Addendum zum Auftrag A15-15) (Version 1.0; Status: 24 September 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 24 September 2015 1.0 Commission: A15-36 Version: Status: IQWiG Reports – Commission No. A15-36 Insulin degludec (...) /liraglutide (Addendum to Commission A15-15) 1 Addendum A15-36 Version 1.0 Insulin degludec/liraglutide (Addendum to Commission A15-15) 24 September 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide (Addendum to Commission A15-15) Commissioning agency: Federal Joint Committee Commission awarded on: 8 September 2015 Internal Commission No.: A15-36 Address of publisher

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

299. Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)

Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Insulin degludec/Liraglutid (neues Anwendungsgebiet) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11. November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A15-30 Insulin degludec/liraglutide (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-30 Version 1.0 Insulin degludec/liraglutide (new TI) – Benefit assessment acc. to §35a SGB V 11 Nov 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide (new

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

300. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo)

Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) T T ype 2 diabetes mellitus in adults: high-strength ype 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (T insulin glargine 300 units/ml (T oujeo oujeo) ) Evidence summary Published: 2 December 2015 nice.org.uk/guidance/esnm65 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in December 2015. See summaries (...) of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary High-strength insulin products such as insulin glargine 300 units/ml (T oujeo) have been developed for people with type 1 or type 2 diabetes who have large daily insulin requirements to reduce the number and volume of injections. In 3 randomised controlled trials (RCTs) in 2496 adults with type 2 diabetes, T oujeo had similar efficacy to insulin glargine 100 units/ml

2015 National Institute for Health and Clinical Excellence - Advice